|
|
Article: Zapaq Plans $14M Financing To Exploit Alzheimer's Discoveries.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Zapaq Inc. was the first company to receive seed money to develop drugs for Alzheimer's disease from the Institute for the Study of Aging under the institute's Founders Program.
Zapaq is a start-up company that initially is focusing on developing drugs for Alzheimer's disease based on inhibiting an enzyme involved in the production of beta-amyloid, a protein that is considered a key factor in Alzheimer's.
"The company received its first financing in January," Zapaq President and CEO James Jenson said. "That's when we really got going."
While the New York-based institute awarded Zapaq $500,000, the remainder of the total ...